Concepedia

Vilma Sniukiene

VS

Statistics

Publications

20

Citations

3.5K

H-Index

17

Active since

2010

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Johns Hopkins University

Johns Hopkins Medicine

Cedars-Sinai Medical Center

Université de Lorraine

Vilma Sniukiene is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacotherapy, pharmacy, and antiviral therapy.

Publications per year

2010–2019

20

Publications

20

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

Fred Poordad, Jonathan McCone, Bruce R. Bacon et al. · New England Journal of Medicine · 2011 · 2.5K citations · Full text

, , +17

Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir

Fred Poordad, Jean–Pierre Bronowicki, Stuart C. Gordon et al. · Gastroenterology · 2012 · 193 citations · Full text

, , +12

High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin

Stefan Wirth, Carmen Ribes‐Koninckx, Maria Angeles Calzado et al. · Journal of Hepatology · 2010 · 147 citations

, , +14

12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY

F. Poordad, J.-P. Bronowicki, Stuart C. Gordon et al. · Journal of Hepatology · 2011 · 90 citations · Full text

, , +14

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial

Mark S. Sulkowski, Fred Poordad, M.P. Manns et al. · Hepatology · 2012 · 73 citations · Full text

, , +17

1–5 of 20